13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
300 檔
22.0%
The Q1 2026 SEC filing reveals that ADAR1 Capital Management, LLC held a total portfolio value of $2.2B, covering 300 public equity positions.
In Q1 2026, ADAR1 Capital Management, LLC displayed an active expansion posture, initiating 49 new positions and adding to 72 existing holdings, outstripping position reductions.
Showing top 200 holdings (of 300 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 9.43% | +1.85% | +9.16% | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 6.17% | -0.78% | -5.25% | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 5.36% | -0.25% | -4.17% | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 3.92% | +0.19% | +7.98% | |
| 5 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.46% | -3.46% | EXIT | |
| 6 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 2.91% | +2.36% | +38.87% | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.45% | -0.66% | +17.10% | |
| 8 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.44% | -0.35% | +268.28% | |
| 9 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 2.31% | -0.50% | — | |
| 10 | DNLI | Denali Therapeutics Inc | Stock-Other | 2.12% | -0.91% | +3490.94% | |
| 11 | BEAM | Beam Therapeutics Inc | Stock-Other | 2.03% | -2.03% | EXIT | |
| 12 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.58% | +1.35% | +14.35% | |
| 13 | SEPN | Septerna Inc | Stock-Other | 1.54% | -0.10% | -5.86% | |
| 14 | VIR | Vir Biotechnology Inc | Stock-Other | 1.45% | -0.30% | — | |
| 15 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.25% | -0.85% | — | |
| 16 | AVR | Anteris Technologies Global | Stock-Other | 1.24% | +0.18% | +205.88% | |
| 17 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.23% | -0.47% | +2601.31% | |
| 18 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.18% | -1.18% | EXIT | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.08% | -0.39% | +311.79% | |
| 20 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.00% | +0.15% | +893.58% | |
| 21 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.94% | -0.36% | -20.37% | |
| 22 | PRTA | Prothena Corporation plc | Stock-Other | 0.90% | -0.20% | +8.48% | |
| 23 | SNY | Sanofi-adr | Stock-Healthcare | 0.90% | -0.79% | +399.32% | |
| 24 | PCVX | Vaxcyte Inc | Stock-Other | 0.89% | -0.50% | -17.90% | |
| 25 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.85% | +0.07% | +12.98% | |
| 26 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.83% | -0.55% | -42.14% | |
| 27 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.82% | -0.38% | +12.38% | |
| 28 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.80% | +0.26% | -33.85% | |
| 29 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.78% | +0.17% | +19.38% | |
| 30 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.78% | -0.32% | +12.22% | |
| 31 | STRO | Sutro Biopharma Inc | Stock-Other | 0.77% | -0.16% | +681.85% | |
| 32 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.77% | -0.02% | -7.71% | |
| 33 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.76% | +0.14% | +998.47% | |
| 34 | REPL | Replimune Group Inc | Stock-Other | 0.76% | -0.43% | +32.90% | |
| 35 | CGON | Cg Oncology Inc | Stock-Other | 0.74% | -0.35% | -28.06% | |
| 36 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 0.73% | -0.16% | — | |
| 37 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.71% | +0.02% | +24.53% | |
| 38 | IVA | Inventiva SA - Adr | Stock-Other | 0.71% | -0.09% | -19.76% | |
| 39 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.71% | -0.11% | +8.98% | |
| 40 | NKTR | Nektar Therapeutics | Stock-Other | 0.68% | +0.10% | +123.86% | |
| 41 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.65% | +0.04% | -18.07% | |
| 42 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.64% | -0.42% | +268.41% | |
| 43 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.61% | -0.12% | — | |
| 44 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.59% | +0.32% | +6.05% | |
| 45 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.59% | -0.12% | +140.09% | |
| 46 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.55% | +0.08% | +0.85% | |
| 47 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.52% | -0.50% | — | |
| 48 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.50% | -0.17% | +5.33% | |
| 49 | IRD | Opus Genetics Inc | Stock-Other | 0.50% | -0.16% | +4522.51% | |
| 50 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.48% | -0.05% | +13.74% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNLI | Denali Therapeutics Inc | +2.1% | +3490.94% | Add |
| 2 | 430 | Terns Pharmaceuticals Inc | +1.9% | +105.81% | Add |
| 3 | CRNX | Crinetics Pharmaceuticals In | +1.4% | +268.28% | Add |
| 4 | INSP | Inspire Medical Systems Inc | +1.1% | +2601.31% | Add |
| 5 | SRRK | Scholar Rock Holding CORP | +1% | +485.25% | Add |
| 6 | SYRE | Spyre Therapeutics Inc | +0.9% | +893.58% | Add |
| 7 | AVR | Anteris Technologies Global | +0.8% | +205.88% | Add |
| 8 | ELVN | Enliven Therapeutics Inc | +0.7% | +998.47% | Add |
| 9 | STRO | Sutro Biopharma Inc | +0.7% | +681.85% | Add |
| 10 | RYTM | Rhythm Pharmaceuticals Inc | +0.7% | +311.79% | Add |
| 11 | SNY | Sanofi-adr | +0.7% | +399.32% | Add |
| 12 | IRD | Opus Genetics Inc | +0.5% | +4522.51% | Add |
| 13 | NKTR | Nektar Therapeutics | +0.5% | +123.86% | Add |
| 14 | OKUR | Onkure Therapeutics Inc-a | +0.4% | +140.09% | Add |
| 15 | VKTX | Viking Therapeutics Inc | +0.4% | +759.50% | Add |
| 16 | SPRY | Ars Pharmaceuticals Inc | +0.3% | +268.41% | Add |
| 17 | SRPT | Sarepta Therapeutics Inc | +0.3% | +807.84% | Add |
| 18 | LONA | Leonabio Inc | +0.2% | +84.78% | Add |
| 19 | PLRX | Pliant Therapeutics Inc | +0.2% | +3401.98% | Add |
| 20 | RLMD | Relmada Therapeutics Inc | +0.2% | +1364.13% | Add |
| 21 | SPY | Ss Spdr S&p 500 ETF Trust-us | +0.2% | +38.87% | Add |
| 22 | VRDN | Viridian Therapeutics Inc | +0.2% | +294.34% | Add |
| 23 | ABOS | Acumen Pharmaceuticals Inc | +0.2% | +141.96% | Add |
| 24 | LQDA | Liquidia CORP | +0.2% | +308.16% | Add |
| 25 | CATX | Perspective Therapeutics Inc | +0.2% | +687.17% | Add |
| 26 | PEPG | Pepgen Inc | +0.2% | +4263.60% | Add |
| 27 | URGN | UroGen Pharma Ltd. | +0.1% | +139.13% | Add |
| 28 | TENX | Tenax Therapeutics Inc | +0.1% | +235.25% | Add |
| 29 | APLSUSD | Apellis Pharmaceuticals Inc | +0.1% | +262.50% | Add |
| 30 | DRUG | Bright Minds Biosciences Inc | +0.1% | +868.57% | Add |
| 31 | XENE | Xenon Pharmaceuticals Inc | +0.1% | +12.22% | Add |
| 32 | OVID | Ovid Therapeutics Inc | +0.1% | +6.05% | Add |
| 33 | KPTI | Karyopharm Therapeutics Inc | +0.1% | +583.87% | Add |
| 34 | ACLXGBX | Arcellx Inc | +0.1% | +1.91% | Add |
| 35 | SLN | Silence Therapeutics Plc-adr | 0% | +628.15% | Add |
| 36 | AMLX | Amylyx Pharmaceuticals Inc | 0% | +12.38% | Add |
| 37 | CRBP | Corbus Pharmaceuticals Holdi | 0% | +27.90% | Add |
| 38 | KROS | Keros Therapeutics Inc | 0% | +416.25% | Add |
| 39 | BCRX | Biocryst Pharmaceuticals Inc | 0% | +133.33% | Add |
| 40 | FWRD | Forward Air CORP | 0% | +193.75% | Add |
| 41 | VYNE | Vyne Therapeutics Inc | 0% | +319.20% | Add |
| 42 | EVMN | Evommune Inc | 0% | — | Unchanged |
| 43 | MASI* | Masimo CORP | 0% | — | Unchanged |
| 44 | 260 | Centessa Pharmaceuticals-adr | 0% | — | Unchanged |
| 45 | RARE | Ultragenyx Pharmaceutical In | 0% | +234.00% | Add |
| 46 | WHWK | Whitehawk Therapeutics Inc | 0% | +65.61% | Add |
| 47 | PHVS | Pharvaris N.V. | 0% | +23.38% | Add |
| 48 | BIOA | Bioage Labs Inc | 0% | — | Unchanged |
| 49 | CNTX | Context Therapeutics Inc | 0% | — | Unchanged |
| 50 | ORKA | Oruka Therapeutics Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 300 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, PTGX, ROIV) accounted for 22.0% of total reported equity market value during Q1 2026.
Top New Position Initiated
BEAM
市值: $34.5M
Top Position Liquidated / Trimmed
RNAGBP
前期市值: $39.4M
During Q1 2026, ADAR1 Capital Management, LLC's top holdings by market value included ABVX (9.4%)、PTGX (6.2%)、ROIV (5.4%). The largest single position, ABVX, represented 9.4% of total portfolio value.
In Q1 2026, ADAR1 Capital Management, LLC made 189 total portfolio adjustments, initiating 49 new buys, adding to 72 positions, trimming 44 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.